Citronellol potentiates sunitinib efficacy in renal cell carcinoma by targeting JAK2/STAT3 signaling pathway
Naunyn-Schmiedeberg's Archives of Pharmacology · 2026-05 · 399 (8) · 12141-12155
DOI: 10.1007/s00210-026-05096-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, online erschienen am 05.03.2026. Verfasst von Zongrun Sun und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Tongren Hospital Shanghai Jiao Tong University School of Medicine, No.1111 Xian Xia Road, Shanghai, 200336, China. Hauptthemen laut MEDLINE: Acyclic Monoterpenes, Antineoplastic Agents, Carcinoma, Renal Cell, Janus Kinase 2. Die Arbeit nennt 27 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Renal cell carcinoma. (RCC) is the most common form of kidney cancer and frequently develops resistance to tyrosine kinase inhibitors (TKIs), such as sunitinib, limiting treatment efficacy. To address this challenge, we investigated the potential of Citronellol, a plant-derived monoterpenoid, to enhance sunitinib sensitivity in RCC. Through network pharmacology analysis, the potential targets of Citronellol were identified, and it was confirmed that it may exert anticancer effects through the EGFR and JAK2/STAT3 signaling pathways. In vitro experimental results showed that Citronellol significantly inhibited the proliferation and migration of 786-O and A498 cells and induced apoptosis. Furthermore, when combined with sunitinib treatment, Citronellol significantly reduced the IC50 value of sunitinib and enhanced its inhibitory effect on renal cancer cells. Western blot results further revealed that Citronellol significantly inhibited the phosphorylation of EGFR, JAK2, and STAT3, suggesting that it may enhance the anticancer activity of sunitinib by inhibiting the survival signals mediated by the JAK2/STAT3 signaling pathway. This study is the first to systematically reveal that Citronellol enhances the therapeutic effect of sunitinib in RCC cells by modulating the JAK2/STAT3 signaling pathways. These findings suggest a promising combination strategy for overcoming TKI resistance and improving RCC treatment outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Tongren Hospital Shanghai Jiao Tong University School of Medicine, No.1111 Xian Xia Road, Shanghai, 200336, China.
- College of Medicine, Yanbian University, Yanji, 133002, China.
- Center for Rare Diseases, State Key Laboratory of Complex, Severe, and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730, China.
- School of Life Sciences, Bengbu Medical University, Bengbu, 233000, China.
- Department of Urology, Tongren Hospital Shanghai Jiao Tong University School of Medicine, No.1111 Xian Xia Road, Shanghai, 200336, China. jiaxing92222@163.com.
- Department of Urology, Tongren Hospital Shanghai Jiao Tong University School of Medicine, No.1111 Xian Xia Road, Shanghai, 200336, China. lm4104@shtrhospital.com.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Sun, Z., Chen, Z., Cai, Y., Yin, G., Song, Y., Jia, X., & Liu, M. (2026). Citronellol potentiates sunitinib efficacy in renal cell carcinoma by targeting JAK2/STAT3 signaling pathway. Naunyn-Schmiedeberg's Archives of Pharmacology, 399(8), 12141-12155. https://doi.org/10.1007/s00210-026-05096-0
Vancouver
Sun Z, Chen Z, Cai Y, Yin G, Song Y, Jia X, et al. Citronellol potentiates sunitinib efficacy in renal cell carcinoma by targeting JAK2/STAT3 signaling pathway. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026;399(8):12141-12155. doi:10.1007/s00210-026-05096-0
BibTeX
@article{Sun2026,
author = {Sun, Zongrun and Chen, Zixuan and Cai, Yuesong and Yin, Guohuan and Song, Ya and Jia, Xing and Liu, Min},
title = {Citronellol potentiates sunitinib efficacy in renal cell carcinoma by targeting JAK2/STAT3 signaling pathway},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2026},
volume = {399},
number = {8},
pages = {12141--12155},
doi = {10.1007/s00210-026-05096-0}
}
EUVIMED